Am J Obstet Gynecol
- MAI PL, Miller A, Black A, Falk RT, et al
Effect of Risk-Reducing Salpingo-Oophorectomy on Sex-Steroid Hormone Serum Levels
among Post-Menopausal Women: An NRG Oncology/GOG Study.
Am J Obstet Gynecol. 2022 Feb 22. pii: S0002-9378(22)00124.
BMC Cancer
- KENNEDY F, Shearsmith L, Holmes M, Rogers Z, et al
Electronic patient-reported monitoring of symptoms during follow-up of ovarian
cancer patients: a feasibility study.
BMC Cancer. 2022;22:726.
Br J Cancer
- NICHOLSON HA, Sawers L, Clarke RG, Hiom KJ, et al
Fibroblast growth factor signalling influences homologous recombination-mediated
DNA damage repair to promote drug resistance in ovarian cancer.
Br J Cancer. 2022 Jul 1. pii: 10.1038/s41416-022-01899.
Clin Cancer Res
- CHENG Z, Mirza H, Ennis DP, Smith P, et al
The Genomic Landscape of Early-Stage Ovarian High-Grade Serous Carcinoma.
Clin Cancer Res. 2022 Apr 10:OF1-OF12. doi: 10.1158/1078-0432.CCR-21-1643.
Gynecol Oncol
- WALL JA, Lipking K, Smith HJ, Huh WK, et al
Moderate to severe distress in half of ovarian cancer patients undergoing
treatment highlights a need for more proactive symptom and psychosocial
management.
Gynecol Oncol. 2022 Jun 28. pii: S0090-8258(22)00420.
Hum Pathol
- LONDERO AP, Orsaria M, Viola L, Marzinotto S, et al
Survivin, Sonic hedgehog, Kruppel-like factors, and p53 pathway in serous ovarian
cancer: an immunohistochemical study.
Hum Pathol. 2022 Jun 28. pii: S0046-8177(22)00168.
Int J Cancer
- ATWAL A, Snowsill T, Dandy MC, Krum T, et al
The prevalence of mismatch repair deficiency in ovarian cancer: A systematic
review and meta-analysis.
Int J Cancer. 2022 Jun 15. doi: 10.1002/ijc.34165.
Lancet Oncol
- CLAMP AR, James EC, McNeish IA, Dean A, et al
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube,
or primary peritoneal cancer treatment (ICON8): overall survival results from an
open-label, randomised, controlled, phase 3 trial.
Lancet Oncol. 2022;23:919-930.
Free Medical Abstracts
Privacy Policy
Sponsors
Share
© Amedeo 1997-2016